Dear [redacted]

NICE has asked for comments on the provisional report. In particular:

- Has all of the relevant evidence been taken into account?
- Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?
- Are the provisional recommendations sound and a suitable basis for guidance to the NHS?

I would suggest that NICE has not taken all the evidence into account as the provisional recommendations do not appear to address any of the concerns raised by patients or patient representative bodies, such as Ovacome. They do nothing to answer the concerns of the unnecessary deaths experienced in the UK caused by poor treatment referenced in our initial submission.
Choosing which treatments to offer/accept in the relapsed setting is challenging enough. The current provisional recommendations were characterised by one colleague as being akin to running an already unseaworthy boat into an iceberg.
In reducing the available resources NICE is reducing the possibility of individualised and patient centred care. We therefore do not feel that the guidance can be considered sound.

Yours sincerely

[redacted]

ovacome..

the ovarian cancer support charity